· clinical-corner · 10 min read
Decades of animal data, almost no human trials. The regulatory, IP, and funding reasons BPC-157 keeps stalling in preclinical — and what the July 2026 FDA PCAC vote could change.
BPC-157 (Body Protection Compound 157) is one of the most-discussed research peptides on the internet and one of the least-studied in formal clinical settings. Animal data on tendon repair, gut healing, and angiogenesis goes back to the 1990s. Human trials — the kind that would establish safety, dosing, and pharmacokinetics in a regulated setting — are almost nonexistent. This piece explains why.
BPC-157 is a 15-amino-acid fragment isolated from a protective protein in human gastric juice. Preclinical literature is unusually deep for a peptide that has never received marketing approval anywhere in the world. Most published work comes from a single research group at the University of Zagreb, supplemented by smaller groups in China, Japan, and the U.S. For a class-level overview, see our A–Z compound directory.
| Study type | Approximate count | Status |
|---|---|---|
| In vitro / cell-line | 100+ | Ongoing |
| Rodent in-vivo | 150+ | Ongoing, mostly Zagreb group |
| Larger-animal preclinical | <10 | Sparse |
| Registered human trials (ClinicalTrials.gov) | 2 small | One terminated, one unknown status |
| Phase 2/3 human trials | 0 | None active |
Drug development is economically driven. To justify the $1B+ cost of bringing a new molecule through Phase 1–3, a sponsor needs a defensible commercial position at the end. BPC-157 fails that test in four specific ways.
| Barrier | What it means | Impact |
|---|---|---|
| No composition-of-matter patent | The sequence has been public since the 1990s | Cannot be patented as a new chemical entity |
| No FDA-approved formulation | Never gone through IND/NDA | Sponsor would carry the entire dev cost alone |
| Generic threat at launch | Any compounder could replicate the sequence | Erodes pricing power on day one |
| Soft indication landscape | Tendinopathy, IBD-adjacent, ulcer healing — all crowded | No clear orphan or unmet-need pathway |
Method-of-use and formulation patents are theoretically possible, but they are weak compared with composition-of-matter and are easy to engineer around. No major or mid-cap pharma has filed a serious IND program around BPC-157.
In the U.S., BPC-157 sits in a regulatory gap. It is not FDA-approved for any human indication. It was historically compounded under FDA §503A by traditional pharmacies, but a 2023 FDA Compounding Pharmacy Advisory Committee evaluation placed it in Category 2 — meaning "significant safety risks identified." That effectively removed it from the legal compounding supply chain for most patients. For background, see our FDA peptide compounding explainer.
The FDA reconvened the Pharmacy Compounding Advisory Committee in July 2026 to revisit BPC-157 alongside six other peptides being considered for the 503A bulk substances list. A "yes" vote would create a regulated U.S. compounding pathway. A "no" vote would essentially end legal U.S. supply for clinicians. Either outcome is significant for whether human trials become feasible — see our BPC-157 FDA review explainer for what is and isn't on the table.
Clinical trials cost money. For BPC-157, no obvious funder exists.
| Funder type | Why they have not stepped up |
|---|---|
| Big pharma | No patent runway, no defensible margin |
| NIH / federal grants | Few applications filed; no academic champion at top U.S. institutions |
| Patient-advocacy foundations | No single indication is large enough to mobilize a community |
| Compounding pharmacies | Cannot legally fund unapproved-drug trials |
| DoD / VA (tendon repair) | Limited interest without a regulated U.S. supply |
The handful of small human studies that have been run on BPC-157 are pilot-scale and underpowered to draw causal conclusions. They are useful for hypothesis generation, not for safety or efficacy claims.
| Setting | n | Endpoint | Result framing |
|---|---|---|---|
| Oral, ulcerative colitis pilot (Croatia) | ~20 | Symptom scoring | Suggestive, not powered |
| Knee pain observational (private clinic) | <50 | Patient-reported | No control arm |
| Open-label tendinopathy reports | Various, <10 each | Pain VAS | Case-series quality |
| Online self-report surveys | Hundreds | Self-reported recovery | Not clinical evidence |
None of this clears the bar required by the FDA for an efficacy claim. For neutral background on the underlying mechanism, see the glossary and the research guides library.